Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 8065SC

8065SC 10 µg (With Carrier) $199.00
8065SF 10 µg (Carrier Free) $199.00
8065LC 50 µg (With Carrier) $599.00
8065LF 50 µg (Carrier Free) $599.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human VEGF165 (hVEGF165) Ala207-Arg371 (Accession #NP_001020539) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hVEGF165. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hVEGF165 contains no "tags" and has a calculated MW of 19,165. DTT-reduced protein migrates as a 24 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 40 kDa protein. The expected amino-terminal APMAE of recombinant hVEGF165 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hVEGF165 was determined in a cell proliferation assay using HUVEC. The ED50 of each lot is between 1-6 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1μg hVEGF165.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hVEGF165. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

VEGF165 is the most abundant splice variant of VEGF-A (1,2). VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability (1). VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes (1,2). VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix (2,3). VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2 (1). VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 (1-3) that function to enhance VEGFR2 signaling (1). Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin (1). VEGF plays a key role in tumor angiogenesis in many cancers (2).


1.  Takahashi, H. and Shibuya, M. (2005) Clin Sci (Lond) 109, 227-41.

2.  Neufeld, G. et al. (1999) FASEB J 13, 9-22.

3.  Robinson, C.J. and Stringer, S.E. (2001) J Cell Sci 114, 853-65.


Entrez-Gene Id 7422
Swiss-Prot Acc. P15692


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.